800
Participants
Start Date
January 31, 2005
Primary Completion Date
January 31, 2006
Study Completion Date
January 31, 2006
rituximab
Pixantrone (BBR 2778)
New York University, New York
North Shore - Long Island Jewish Health System, New Hyde Park
HemOnCare, P.C., Brooklyn
South Shore Hematology-Oncology Associates, Rockville Centre
Glens Falls Cancer Center, Glens Falls
Upstate NY Cancer Research, Rochester
Blair Medical Associates, Altoona
Lancaster Cancer Center, LTD, Lancaster
Santee Hematology Oncology, Sumter
Orange Park Cancer Center, Orange Park
Ocala Oncology Center, Ocala
The West Clinic, Memphis
Commonwealth Hematology/Oncology, Danville
Private Practice, Canton
Hope Center, Terre Haute
Oncology of Wisconsin, Glendale
Marshfield Clinic, Marshfield
Rhinelander Regional Medical Group Onc., Rhinelander
Hematology - Oncology Centers of N. Rockies, Billings
Great Falls Clinic, Great Falls
Edward Cancer Center, Naperville
University of Chicago Medical Center Hematology / Oncology, Chicago
Illinois Masonic Cancer Center, Chicago
Christian Hospital, St Louis
St. Johns Mercy Medical Center, St Louis
St. Joseph Oncology, Saint Joseph
Rocky Moutain Cancer Center, Denver
Central Utah Medical Clinic Hematology-Oncology, Provo
Arizona Clinical Research Center, Tucson
New Mexico Oncology / Hematology, Albuquerque
Kenmar Research Institute, Los Angeles
Sutter Health Western Division Cancer Research Group, Greenbrae
Pasco, Hernando Oncology Associates, P.A., New Port Richey
Clinworks, Inc, Charlotte
New England Hematology / Oncology Associates, Wellesley
East Orange VA Medical Center, East Orange
Hematology Oncology Associates of NJ, Paramus
Summit Medical Group/Overlook Onc Center, Summit
Lead Sponsor
CTI BioPharma
INDUSTRY